In the tumor xenografts, IHC staining demonstrated enzalutamide treatment reduced the expression of both KLF5 and AR, which is consistent with in vitro findings (Figure 1g–l), and KLF5 silencing also downregulated AR expression (Figure 6g,h). This evidence concerns the gene AR and neoplasm.